429 related articles for article (PubMed ID: 14628501)
1. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
Swerdloff RS; Wang C
Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
3. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
[TBL] [Abstract][Full Text] [Related]
4. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
Behre HM; Heinemann L; Morales A; Pexman-Fieth C
Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
[TBL] [Abstract][Full Text] [Related]
7. [Should older men be treated with testosterone?].
Svartberg J
Tidsskr Nor Laegeforen; 2005 Apr; 125(7):879-82. PubMed ID: 15815734
[TBL] [Abstract][Full Text] [Related]
8. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N;
J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
[TBL] [Abstract][Full Text] [Related]
9. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
10. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
Ebert T; Jockenhövel F; Morales A; Shabsigh R
Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
12. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
13. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
Asscheman H; Gooren LJ
Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775
[TBL] [Abstract][Full Text] [Related]
14. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices.
Miner M; Canty DJ; Shabsigh R
Postgrad Med; 2008 Sep; 120(3):130-53. PubMed ID: 18824832
[TBL] [Abstract][Full Text] [Related]
15. Testosterone in older men after the Institute of Medicine Report: where do we go from here?
Harman SM
Climacteric; 2005 Jun; 8(2):124-35. PubMed ID: 16096168
[TBL] [Abstract][Full Text] [Related]
16. Androgens and the ageing male.
Swerdloff RS; Wang C
Best Pract Res Clin Endocrinol Metab; 2004 Sep; 18(3):349-62. PubMed ID: 15261842
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients.
Ferreira U; Leitao VA; Denardi F; Matheus WE; Stopiglia RM; Netto NR
Prostate Cancer Prostatic Dis; 2006; 9(1):39-41. PubMed ID: 16276352
[TBL] [Abstract][Full Text] [Related]
18. Testosterone supplementation: what and how to give.
Jockenhövel F
Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500
[TBL] [Abstract][Full Text] [Related]
19. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
Morales A; Black AM; Emerson LE
BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
[TBL] [Abstract][Full Text] [Related]
20. Testosterone metabolism and replacement therapy in patients with end-stage renal disease.
Johansen KL
Semin Dial; 2004; 17(3):202-8. PubMed ID: 15144546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]